Determining rates of hepatitis C in a clozapine treated cohort

Schizophrenia Research

Volumn 124, Issue 1-3, 2010, Pages 86-90

  Sockalingam, Sanjeev ^a,d   Shammi, Chekkera ^b,c,d   Powell, Valerie ^c   Barker, Lucy ^c   Remington, Gary ^c,d,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Schizophrenia Program   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Medication Assessment Program for Schizophrenia   (Canada)

Author keywords

Clozapine; Hepatitis C; Liver disease; Schizophrenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLOZAPINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD TRANSFUSION; BODY PIERCING; CANADA; COCAINE DEPENDENCE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SEXUAL BEHAVIOR; TATTOO; THROMBOCYTE COUNT; TREATMENT DURATION;

ADMINISTRATION, INTRANASAL; ADULT; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; CANADA; CLOZAPINE; COCAINE-RELATED DISORDERS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISK FACTORS; RISK-TAKING; SCHIZOPHRENIA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 78249287208     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.06.005     Document Type: Article

References (33)

1. Al Jurdi R.W., Burruss J.W. Prevalence of hepatitis C in psychiatric institutions. Psychosomatics 2003, 44:439-440.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J. Med. 1999, 341:556-562.
3. Bini E.J., Brau N., Currie S., Shen H., Anand B.S., Hu K., et al. Prospective multicenter study of eligibility for antiviral therapy among 4, 084 U.S. veterans with chronic hepatitis C virus infection. Am. J. Gastroenterol. 2005, 100:1772-1779.
4. Cheng Y.C., Chen C.C., Ho A.S., Chiu N.Y. Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review. Psychosomatics 2009, 50(5):538-542.
5. Dieperink E., Willenbring M.L., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 2000, 157:867-876.
6. Dinwiddie S.H., Shicher L., Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am. J. Psychiatry 2003, 160:172-174.
7. Essock S.M., Dowden S., Constantine N.T., Katz L., Swartz M.S., Meador K.G., et al. Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. Psychiatr. Serv. 2003, 54(6):836-841.
8. Essock S.M., Dowden S., Constantine N.T., Katz L., Swartz M.S., Meador K.G., et al. Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. Psychiatr. Serv. 2003, 54:836-841.
9. Evon D.M., Verma A., Dougherty K.A., Batey B., Russo M., Zacks S., et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig. Dis. Sci. 2007, 52:3251-3258.
10. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996, 24:38-47.
11. Freudenreich O., Gandhi R.T., Walsh J.P., Henderson D.C., Goff D.C. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics 2007, 48(5):405-411.
12. Himelhoch S., McCarthy J.F., Ganoczy D., Medoff D., Kilbourne A., Goldberg R., et al. Understanding associations between serious mental illness and hepatitis C among veterans: a national multivariate analysis. Psychosomatics 2009, 50(1):30-37.
13. Hosoda S., Takimura H., Shibayama M., Kanamura H., Ikeda K., Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin. Neurosci. 2000, 54:565-572.
14. Huckans M., Mitchell A., Pavawalla S., Morasco B.J., Ruimy S., Loftis J.M., et al. The influence of antiviral therapy on psychiatric symtoms among patients with hepatitis C and schizophrenia. Antivir. Ther. 2010, 15(1):111-119.
15. Huckans M., Mitchell A., Ruimy S., Loftis J.M., Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr. Bull. 2010, 36(1):165-172.
16. Johnson M.E., Fisher D.G., Fenaughty A., Theno S.A. Hepatitis C virus and depression in drug users. Am. J. Gastroenterol. 1998, 93:785-789.
17. Kerr C., Kerr T., Li K., Zhang R., Tyndall M.W., Montaner J.S., et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health 2009, 29:270.
18. Liukkonen T., Sorjonen M., Jokelainen J., Timonen M. Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment. Psychosomatics 2008, 49(1):86-88.
19. Matthews A.M., Huckans M.S., Blackwell A.D., Hauser P. Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord. 2008, 10:266-270.
20. Nakamura Y., Koh M., Miyoshi E., Ida O., Morikawa M., Tokuyama A., et al. High prevalence of the hepatitis C infection among the inpatients of schizophrenia and psychoactive sbstance abuse in Japan. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:591-597.
21. Pirl W.F., Greer J.A., Weissgarber C., Liverant G., Safren S.A. Screening for infectious diseases among patients in a state psychiatric hospital. Psychiatr. Serv. 2005, 56(12):1614-1616.
22. Plebani J.G., Tirado C.F., Pettinati H.M., Kampman K.M., Volpicelli J.R., Oslin D.W. Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addict. Behav. 2010, 35(2):123-128.
23. Rosenberg S., Brunette M., Oxman T., Marsh B., Dietrich A., Mueser K., et al. The STIRR model of best practices for blood-borne diseases among clients with serious mental illness. Psychiatr. Serv. 2004, 55:660-664.
24. Rosenberg S.D., Goodman L.A., Osher F.C., Swartz M.S., Essock S.M., Butterfield M.I., et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am. J. Public Health 2001, 91(1):31-37.
25. Rothbard A.B., Blank M.B., Staab J.P., Tenhave T., Young D.S., Berry S.D., et al. Previously undetected metabolic syndromes and infectious diseases among psychiatric inpatients. Psychiatr. Serv. 2009, 60(4):534-537.
26. Saunders J.B., Aasland O.G., Babor T.F., de la Puente J.R., Grant M. Development of the Alcohol Use Disorders Screening Test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction 1993, 88:791-804.
27. Schaefer M., Hintzpeter A., Mohmand A., Janssen G., Pich M., Schwaiger M., et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007, 46:991-998.
28. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
29. Telio D., Sockalingam S., Stergiopoulos V. Persistent psychosis after treatment with interferon alfa: a case report. J Clin. Psychopharmocol. 2006, 26(4):446-447.
30. Thome J., Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a. Eur. Psychiatry 2003, 18(3):142-143.
31. Van Thiel D.H., Friedlander L., Molloy P.J., Fagiuoli S., Kania R.J., Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur. J. Gastroenterol. Hepatol. 1995, 7:165-168.
32. WHO Hepatitis C: global prevalence. Wkly Epidemiol. Rec. 1997, 72:341-344.
33. Zou S., Tepper M., Giulivi A. Current status of hepatitis C in Canada. Can. J. Public Health 2000, 91:S10-S16.